Abstract: A method of treating Middle East Respiratory syndrome (MERS) includes administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising fisetin and a pharmaceutically acceptable carrier.
Type:
Grant
Filed:
May 3, 2024
Date of Patent:
January 28, 2025
Assignee:
KING SAUD UNIVERSITY
Inventors:
Ahmed Lafi Alaofi, Mudassar Ahmad Shahid
Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Type:
Grant
Filed:
July 2, 2021
Date of Patent:
January 14, 2025
Assignee:
Evoke Pharma, Inc.
Inventors:
Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
Abstract: Nasal formulations of metoclopramide, which remain stable and/or colorless upon storage over a period of time, are provided. Also provided are methods of treating disorders treatable with metoclopramide, comprising administering the nasal solutions to patients in need thereof.
Type:
Grant
Filed:
July 2, 2021
Date of Patent:
January 14, 2025
Assignee:
Evoke Pharma, Inc.
Inventors:
Matthew J. D'Onofrio, David A. Gonyer, Shirish A. Shah, Stuart J. Madden
Abstract: A 6-(6-bromo-2-oxo-2H-chromen-3-yl)-4-(3-bromophenyl)-2-alkoxynicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.
Type:
Grant
Filed:
October 11, 2023
Date of Patent:
December 24, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: A treatment method for cerebral vasospasm involves determining amounts of let-7b-5p, miR-9-3p, miR-142-3p, miR-15b-5p, miR-17-5p, miR-19b-3p, miR-20a-5p, miR-24-3p, miR-29a-3p, miR-125b-5p, and miR-142-3p in a biological sample obtained from a subject following aneurysmal subarachnoid hemorrhage (aSAH) to identify the subject as having an elevated risk of cerebral vasospasm, and administering a treatment to the subject when the elevated risk of cerebral vasospasm is identified.
Type:
Grant
Filed:
September 7, 2021
Date of Patent:
December 3, 2024
Assignee:
University of Kentucky Research Foundation
Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.
Abstract: The present invention is directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable after dilution for at least about 48 hours when stored at 2° C. to 8° C. The present invention is also directed to pemetrexed formulations comprising a non-aqueous solvent that remains stable for at least about 24 months when stored at 2° C. to 8° C.
Abstract: The presently-disclosed subject matter generally relates to methods for detecting the presence of amylin in a patient's erythrocytes, determining the risk for the development of prediabetes, type-2 diabetes or comorbidities thereof, and methods of treating said diseases and risks.
Type:
Grant
Filed:
November 14, 2019
Date of Patent:
October 15, 2024
Assignee:
University of Kentucky Research Foundation
Abstract: A method of promoting the generation of oligodendrocytes from oligodendrocyte precursor cells by enhancing their survival and/or maturation includes administering to the cell an effective amount of an agent that enhances and/or induces accumulation of 8,9-unsaturated sterols in the OPCs, the agent comprising a compound having the formula (I): wherein variables Y1, R1 and R2 are as defined herein.
Abstract: Disclosed are compounds having the following structure: CDK-L-(X)n, where CDK is a CDK4/6 inhibitor group, L is a linking group, X is a radiolabel or hydrogen, n is 1, 2, 3, 4, or 5, and when there are a plurality of X groups, at least one X is a radiolabel. Also described are methods of making and using the compounds. The compounds may be used in PET imaging to quantify CDK4/6 expression in cancers and to treat cancer patients exhibiting tumors which express CDK4/6.
Abstract: Nutritional compositions contain a mixture of ketogenic ingredients including from 80 to 99% weight % 1,3-butanediol (BDO), preferably R-1,3-butanediol, and from 1 to 20 weight % beta-hydroxybutyric acid (BHB), preferably D-beta-hydroxybutyric acid, or an equivalent molar amount of its conjugate base beta-hydroxybutyrate, salts, monoesters, polyesters, or mixtures thereof. In some embodiments, the nutritional compositions for providing ketosis are prepared for oral administration in a solid form, such as bars, bites, tablets, pills or capsules, in a liquid form, such as smoothies, goos, water, carbonated beverages, soft drinks, fermented beverage suspensions, solutions and emulsions, or in a powder form that can be used to prepare drink mixes or can be added as a supplement to other food or drink products. Methods of providing ketosis in a subject include delivering optimal therapeutic ketosis, with rapidity into and extended duration of blood concentrations of D-BHB of between 1 mM and 2.5 mM.
Abstract: The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.
Type:
Grant
Filed:
January 19, 2022
Date of Patent:
August 13, 2024
Assignee:
Beam Therapeutics Inc.
Inventors:
Cory Dane Sago, Gregory Lawrence Hamilton
Abstract: The invention provides compounds of formula I: and salts thereof wherein R1-R5 have any of the meanings described in the specification. The compounds are useful for treating bacterial infections (e.g. tuberculosis).
Type:
Grant
Filed:
November 2, 2021
Date of Patent:
August 13, 2024
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Inventors:
Joel S. Freundlich, David Alland, Matthew B. Neiditch, Pradeep Kumar, Glenn Capodagli, Divya Awasthi, Sean Ekins
Abstract: The present disclosure relates to osteoinductive putties and other implantable compositions for repair of bone defects and other medical uses. Specifically, the technology pertains to carriers for use in implantable compositions, such as osteoinductive putties. The osteoinductive putties are made entirely from donor tissue such as demineralized bone matrix, and the putties have excellent physical properties. The present disclosure relates to osteoinductive putties, carriers, compositions, implants, kits, methods of making and methods of using any of the foregoing.
Abstract: The present invention features improved compounds, especially methods of identifying patients having cancer using biomarkers (e.g., PDE3A, SLFN12 and/or CREB3L1) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., Compounds 1-6 disclosed herein).
Type:
Grant
Filed:
January 28, 2021
Date of Patent:
August 6, 2024
Assignees:
Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
Inventors:
Timothy A. Lewis, Alex Burgin, Monica Schenone, Xiaoyun Wu, Heidi Greulich, Matthew Meyerson, Luc De Waal, Antje Margret Wengner, Knut Eis, Philip Lienau, Ulrike Sack, Martin Lange
Abstract: Methods of inhibiting and/or reducing the occurrences and/or duration of microbial infections, such as rhinovirus and influenza infections, are provided herein. The methods comprise delivering an oral composition comprising at least one Eh-raising compound and at least one zinc compound to a subject.
Abstract: A method of treating an inflammation or a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of: a compound represented by Formula I: or a pharmaceutically acceptable salt thereof, a compound represented by Formula II: and a compound represented by Formula III: wherein the variables in Formulae I, II and III are as defined in the specification.
Type:
Grant
Filed:
April 26, 2016
Date of Patent:
July 2, 2024
Assignee:
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center
Abstract: Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A (A2A) receptor antagonist or a combination of an adenosine-A2A (A2A) receptor antagonist and a programmed cell death protein 1 (PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.
Type:
Grant
Filed:
December 17, 2020
Date of Patent:
July 2, 2024
Assignee:
CORVUS PHARMACEUTICALS, INC.
Inventors:
Stephen Willingham, Richard A. Miller, Po Y. Ho, Ian Mccaffery, Andrew Hotson